Category Archives: "News"

EMD Serono data at CMSC & ACTRIMS Annual Meeting reinforces proven efficacy of rebif
EMD Serono Data at CMSC & ACTRIMS Annual Meeting Reinforces Proven Efficacy of Rebif® (interferon beta-1a) and Demonstrates Continued [...]
Media alert — grow your multiple sclerosis knowledge
Contact: Annie Scully, 201-310-9252, annie.scully@mscare.org MEDIA ALERT Grow Your MS [...]
Acorda Therapeutics to showcase online multiple sclerosis resources at 2014 CMSC/ACTRIMS meeting
Acorda Therapeutics to Showcase Online Multiple Sclerosis Resources at 2014 CMSC/ACTRIMS Meeting 05/27/2014 The award-winning [...]
Genzyme recognizes sixth annual World MS Day
Genzyme Recognizes Sixth Annual World MS Day - Company Supporting Wide Range of Programs to Help Improve the Lives of People Living with [...]
CHMP adopts positive opinion for PLEGRIDY as a treatment for multiple sclerosis in the EU
CHMP Adopts Positive Opinion for PLEGRIDYâ„¢ (Peginterferon Beta-1a) as a Treatment for Multiple Sclerosis in the European Union Friday, [...]
Opexa reaches enrollment target in phase IIb trial of personalizedimmunotherapy for SPMS
Opexa Reaches Enrollment Target in Phase IIb Trial of Personalized Immunotherapy for Secondary Progressive Multiple [...]
Teva announces COPAXONE recognized as “Brand of the Year” by Pharm Exec Magazine
Teva announces COPAXONE® recognized as Brand of the Year by Pharmaceutical Executive Magazine JERUSALEM--(BUSINESS WIRE)--May 8, [...]
Leading multiple sclerosis conference offers continuing education credit for pharmacists
Leading Multiple Sclerosis Conference Offers Continuing Education Credit For Pharmacists The Cooperative Meeting of CMSC & ACTRIMS [...]
New TYSABRI analysis shows improved walking speed in significant number of multiple sclerosis patients
New TYSABRI® Analysis at AAN Annual Meeting Shows Improved Walking Speed in Significant Number of MS Patients Thursday, May 1, 2014 [...]
New data reinforce efficacy of TECFIDERA in multiple sclerosis patients with high disease activity
New Data Reinforce Efficacy of TECFIDERA® (Dimethyl Fumarate) in MS Patients with High Disease Activity Wednesday, April 30, 2014 7:30 [...]
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

Upcoming Testing Periods

WINTER 2024 TESTING PERIOD

Application Deadline: December 6th, 2023

First Day of Testing: Saturday, January 6th, 2024

Last Day of Testing: Saturday, January 20th, 2024

SUMMER 2024 TESTING PERIOD

Application Deadline: May 1st, 2024

First Day of Testing: Saturday, June 1st, 2024

Last Day of Testing: Saturday, June 15th, 2024

Resources

Visit PTC to download a PDF version of the Handbook. Candidates can also apply online.

For more information:

Professional Testing Corporation http://www.ptcny.com/

  • 212-356-0660
  • 1350 Broadway, 17th Floor, New York, NY 10018

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM